Objective To observe the therapeutic effects of nourishing qi and activating blood circulation Chinese medicine combined with conventional western medicine on coronary heart disease(CHD) angina pectoris.Methods Eight-three patients with CHD angina pectoris were randomized into treatment group(53 cases) and control group(30 cases).The treatment group was treated with Chinese medicine of nourishing qi and activating blood circulation combined with conventional western medicine,and control group was treated with conventional western medicine only.The changes of clinical symptoms and electrocardiogram were observed,and serum IL-6 was detected before and after treatment.Results The clinical symptoms of angina pectoris and electrocardiogram were obviously improved,and IL-6 was decreased.The treatment group was better than the control group(P

Purpose:To evaluate the protection of astragalus injection for Doxorubicin (adriamycin)-associated cardiotoxicity. Methods:58 patients were randomized into two groups for this clinical trial. 30 patients were in the test group ,and 28 in control group. Patients in the test group received astragalus injection in 5% glucose solution once every day for two weeks starting three days before adriamycin-based chemotherapy. 28 patients in the control group began to receive oral vitamin E 100 mg twice a day and coenzyme Q10 20 mg three times a day for two weeks. Chemotherapy is the same as that in the test group. Electrocardiogram (ECG) and echocardiogram were employed to evaluate the cardiac function. Results:There was a substantial difference in ejection fracton between the two groups,but the difference was not statistically significant. Statistically significant differences were observed in the two groups with regard to all other parameters,including abnormal changes in ECG and LVIDD、LVISD、A/E、FS. Conclusions:Astragalus injection is a good drug which can prevent the occurrence of acute cardiotoxicity associated with adriamycin. It can also reduce the occurrence of chronic cardiotoxicity.

Objective To study the effects of costimulatory blockade with anti-inducible costim- ulator antibody(ICOS mAb)in combination with CTLA4Ig on prevention of islet allograft rejection. Methods Experimental animals were randomly divided into 4 groups(10 rats in each group).CT- LA4Ig + ICOS mAb group(group A):intraperitoneal injection of CTLA4Ig on day 0,2,4 and ICOS mAb on day 1,3,5 after islet transplantation;ICOSmAb group(group B):intraperitoneal injection of ICOS mAb on day 1,3,5 after islet transplantation;CTLA4Ig group(group C):intraperitoneal injection of CTLA4Ig on day 0,2,4 after islet transplantation;control group(group D):simple islet transplantation.The islet allograft survival and pathological changes in the transplanted islets after transplantation were observed.By using RT-PCR,the expression of IL-2 and IL-10 mRNA in the transplanted islets was detected.The expression of CD4~+ and CD8~+ T cell was detected by flow cy- tometry.Results In group A,the survival time was obviously prolonged as compared with other three groups and the transplanted islets were near normal under a light microscope.As compared with other three groups,the expression of IL-2 mRNA was significantly decreased in group A(P0.05).The expression of CD4~+ and CD8~+ T cell was not obviously up-regulated on the day 21 after transplantation.Conclusion The blockade of costimulatory signals with ICOS mAb in combination with CTLA4Ig has a favorable effects to restrain the rejection of islet transplantation.

Immunosuppression in mice vas induced by intrapelitoneal injection of cyclophosphamide40mg/kg for 3 days. After administration of a decoction of Panax ginseng (5g/kg ) or Trogop-terus dung (5g/kg ), alone or 1 :1 mixture of the above two drugs at doses of 5g/kg and 10g/kg for 7 days, resulted in an increase of thymus gland weight (P

Objective To observe the effects of complex prescription with the effects of replenishing Qi, activating blood and resolving phlegm on the levels of LN and PC-Ⅲ in BALF and the changes of lung tissue and figure in rat with pulmonary fibrosis. Method The rat model of pulmonary fibrosis was established by injecting pinyamycin, then the changes of the levels of LN and PC-Ⅲ in every group (TCM group, model group and control group) in 7, 28 days respectively were observed. Result There was obvious pulmonary fibrosis morphologic change. Lung quotient increased clearly, and the levels of LN and PC-Ⅲ in BALF increased obviously in 28 days (P

Object To optimize the process for the extraction of the original recipe used in the treatment of eczema to give a new ECZEMA SPRAY dosage form Methods The extraction process was studied by orthogonal experimental design as guided by determining the content of paeonol and baicalin in the extract Results The optimal extraction process was to reflux the original recipe with 80% ethanol twice at a bath temperature of about 90 ℃ for 1 5 and 1 0 h respectively The amount of ethanol used for each extraction was 10 and 8 times of the original recipe respectively Conclusion The above extraction process gave the most rational and satisfactory results

Objective To obtain I50 anti-idiotype antibody and identify its activity in vitro.Methods I50 anti-idiotype (Id) antibody gene was amplified from the template of fuse 5-I50 by PCR to construct a prokaryotic expression vector pET25b-I50. The expression of pET25b-I50 in E. coli BL21(DE3) was induced by isopropylthio-β-D-galactopyranoside (IPTG) and was confirmed by SDS-PAGE and Western blot with Ab1(FC2) monoclonal antibody and an anti-hexahistidine tag antibody. The method of dialysis refolding was used to restore the activity of I50 anti-Id antibody, which was measured by Dot-ELISA and lymphocyte proliferation assay. Results The recombinant vector was successfully constructed and the recombinant protein was successfully expressed and purified with 90% purity. The relative molecular weight of the expressed protein was 15 kD, which was in accordance with expectation. The activity of I50 anti-Id antibody could be restored and could promote the proliferation of lymphocyte in a dose-dependent manner. Conclusion These results suggested that I50 anti-Id protein vaccine is likely an option in the therapy against nasopharyngeal carcinoma in vivo.

OBJECTIVE:To systematically review the efficacy of Ginseng polysaccharideinjection combined with radiotherapy or chemotherapy in the treatment of malignancies,and provide evidence-based reference for clinical treatment. METHODS:Re-trieved from CNKI,CBM,VIP,Wanfang Database PubMed,EMBase,Web of Science,randomized controlled trials (RCT) about Ginseng polysaccharideinjection combined with radiotherapy or chemotherapy(test group)versus radiotherapy or chemothera-py alone(control group) in the treatment of malignancies were collected. Meta-analysis was performed by using RevMan5.3 soft-ware after data extract and quality evaluation by Cochrane 5.1.0. RESULTS:Totally 7 RCTs were enrolled,involving 567 patients. Results of Meta-analysis showed,the effective rate [OR=1.99,95%CI(1.27,3.14),P=0.003] and improvement rate of life quality [OR=2.95,95%CI(1.75,4.97),P<0.001] in test group were significantly higher than control group,cell abnormal rate [OR=0.26,95%CI(0.16,0.41),P<0.001] was lower than control group,the differences were statistically significant. There were no obvi-ous adverse reaction in 2 groups. CONCLUSIONS:Ginseng polysaccharideinjection combined with radiotherapy or chemotherapy is effective in the treatment of malignancies.

Objective:To study the anti-proliferative effect of lupeol on human bladder cancer T24 cell line and the regulating mechanism for p53/miR-34a signaling. Methods:CCK-8 assay was performed to evaluate the effects of lupeol at different concentra-tions on cell viability in 24 h and 48 h. Caspase inhibitors were used to identify the subtypes of Caspase during lupeol induced cell death. The effects of lupeol on the expression of total p53 protein and miR-34a were evaluated by western blot and real-time PCR, re-spectively. The effects of lupeol on downstream targets of miR-34a were quantified by real-time PCR. Results:Lupeol could inhibit the proliferation of T24 cells in a dose-dependent manner. The IC50 of lupeol was (77. 23 ± 6. 78) μmol·L-1 in 24 h. Compared with the control group, lupeol could elevate the expressions of p53 and miR-34a (P<0. 01). Moreover, the mRNA expression of miR-34a tar-gets, Bcl-2, CD44 and c-Myc were significantly down-regulated after the treatment with lupeol (P<0. 01). Conclusion:Lupeol can inhibit T24 cell proliferation, which is related with the regulating effects on p53/miR-34a signaling.